StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
OPRX$5.38+3.66%
Fair $5.38+0.0%

OPRX

OptimizeRx Corporation

Healthcare / Health Information ServicesNasdaqCM

$5.38

+0.19 (+3.66%)

Fairly Valued+0.0%Fair Value $5.38Fund rank 29/100 · Data gapFallback financials|
SA 51/C
F-Score: 8/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 32% · confianza 25%

FCF escenarios

weak_data · normalized FCF $4.4M · quality 49.0/100

Data gap 29/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 28/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

51/100

C

Piotroski

8/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: unknownPeriods: 16Warnings: 1unknown: 16
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is 4.0%, below the 5% threshold
Thesis & Journal · OPRXLocal privado en este navegador · OptimizeRx Corporation
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$101M

P/E

14.9x

↓

EV/EBITDA

6.3x

↓

ROE

4.0%

↑

Gross Margin

67.3%

↑

Debt/Equity

0.20

↓
52-Week Range$5
$5$22

TradingView lightweight chart

OPRX price, volumen y niveles de valoración

Último $5.380Periodo -55.2%
Fair value: $5.380

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2010–2025 · 15 años de histórico normalizado

Revenue CAGR

+63.1%

FCF CAGR

—

FCF margin

17.1%

FCF / Net income

3.65x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $109.4M · net income $5.1M · FCF $18.7M

2010-FY → 2025-FY

Gross margin

67.3%— pts

Operating margin

11.0%+2609.0% pts

Net margin

4.7%+2831.7% pts

FCF margin

17.1%+1860.7% pts
MetricTTM
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Income Statement
Revenue$109.4M$109.4M$92.1M$71.5M$62.5M$4.5M$43.3M$24.6M$21.2M$8.4M$6.2M$7.2M$6.5M$4.7M$2.0M$1.1M$71065.00
Net Income$5.1M$5.1M$-20.1M$-17.6M$-11.4M$378079.00$-2.2M$-3.1M$226344.00$-2.1M$-1.5M$-595140.00$-1.0M$-267290.00$-454553.00$-2.1M$-2.0M
EBITDA$16.6M$16.6M$-8.9M$-21.3M$-9.4M$2.3M$-59431.00$-2.4M$496634.00$-1.8M$-1.3M$-263457.00$-761988.00$-73745.00$-267818.00$13.6M$-1.8M
EPS0.270.27-1.10-1.03-0.640.02-0.15-0.230.02-0.21-0.15-0.06-0.12————
Gross Margin67.3%67.3%64.5%60.0%62.4%789.0%55.7%62.8%57.6%70.6%69.9%49.8%50.5%60.2%91.5%——
Operating Margin11.0%11.0%-6.7%-24.5%-19.7%8.0%-4.9%-15.0%0.8%-25.3%-25.5%-8.3%-15.8%-5.7%-22.2%1212.7%-2597.9%
Net Margin4.7%4.7%-21.8%-24.6%-18.3%8.4%-5.1%-12.8%1.1%-25.0%-24.8%-8.2%-15.8%-5.7%-22.2%-190.8%-2827.0%
Balance Sheet
Debt/Equity0.200.200.280.290.00——————————0.000.53
Current Ratio5.375.37———————————————
Cash Flow
Free Cash Flow$18.7M$18.7M$4.4M$-8.1M$10.4M$625717.00$-6.4M$-1.7M$758193.00$-1.5M$-644399.00$513064.00$-63334.00$1.1M$-626263.00$-534609.00$-1.3M
Returns
ROE4.0%4.0%-17.2%-13.9%-9.1%0.3%-4.4%-7.0%1.2%-33.8%-19.7%-6.7%-22.2%-16.0%-32.4%-133.5%-106.1%
Valuation
P/E14.9414.94———————————————
EV/EBITDA6.336.33———————————————
P/B0.800.800.861.792.53————————————
Growth & Yield
Revenue Growth18.8%18.8%28.8%14.5%—-89.6%76.1%16.0%151.5%35.8%-14.0%11.0%39.0%128.4%84.3%1464.1%—
EPS Growth124.5%124.5%-6.8%-60.9%—113.3%34.8%-1250.0%109.5%-40.0%-150.0%50.0%—————

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

20.9%

exigente

EPS terminal req.

$0.48

Spread vs growth

103.6%

5Y implied EPS CAGR

16.4%

exigente

EPS terminal req.

$0.58

Spread vs growth

108.1%

10Y implied EPS CAGR

13.2%

razonable

EPS terminal req.

$0.93

Spread vs growth

111.4%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -55.7%

Total return

-55.7%

Start / end P/E

n/dx → n/dx

EPS bridge

-1.10 → 0.27

Residual

-55.7%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-55.7%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.